Charlottesville, VIRGINIA2 Active Studies

Spinal Muscular Atrophy Clinical Trials in Charlottesville, VIRGINIA

Find 2 actively recruiting spinal muscular atrophy clinical trials in Charlottesville, VIRGINIA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
138
Enrolling

Recruiting Spinal Muscular Atrophy Studies in Charlottesville

About Spinal Muscular Atrophy Clinical Trials in Charlottesville

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 2 spinal muscular atrophy clinical trials recruiting participants in Charlottesville, VIRGINIA. These studies are seeking a combined 138 participants. Research is being sponsored by Nasser Hanna, Hirva Mamdani. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Charlottesville — FAQ

Are there spinal muscular atrophy clinical trials in Charlottesville?

Yes, there are 2 spinal muscular atrophy clinical trials currently recruiting in Charlottesville, VIRGINIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Charlottesville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Charlottesville research site will contact you about next steps.

Are clinical trials in Charlottesville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Charlottesville studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 2 active trials in Charlottesville are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov